Approval expands patient access to first and only antidote for reversal of rivaroxaban or apixaban.
Wednesday, 2 January 2019
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process - Diagnostic and Interventional Cardiology
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process Diagnostic and Interventional Cardiology
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment